share_log

Private Companies Invested in Huadong Medicine Co., Ltd (SZSE:000963) Copped the Brunt of Last Week's CN¥3.4b Market Cap Decline

Private Companies Invested in Huadong Medicine Co., Ltd (SZSE:000963) Copped the Brunt of Last Week's CN¥3.4b Market Cap Decline

投資華東醫藥股份有限公司(深圳證券交易所代碼:000963)的私營公司在上週34億元人民幣的市值下跌中首當其衝
Simply Wall St ·  05/26 23:03

Key Insights

主要見解

  • Significant control over Huadong Medicine by private companies implies that the general public has more power to influence management and governance-related decisions
  • A total of 2 investors have a majority stake in the company with 58% ownership
  • Institutional ownership in Huadong Medicine is 15%
  • 私人公司對華東醫藥的重要控制意味着公衆有更多的權力來影響管理和治理相關決策。
  • 2個投資者持有該公司的大部分股份,佔有58%的所有權。
  • 華東醫藥的機構持股比例爲15%。

To get a sense of who is truly in control of Huadong Medicine Co., Ltd (SZSE:000963), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 58% to be precise, is private companies. Put another way, the group faces the maximum upside potential (or downside risk).

要了解華東醫藥股份有限公司(SZSE:000963)真正的控制者是誰,了解業務的所有權結構至關重要。目前購買公司股票最多的集團是私人公司,精確地說是佔公司約58%的股份。換句話說,該集團面臨着最大的上行潛力(或下行風險)。

And last week, private companies endured the biggest losses as the stock fell by 5.9%.

上週,隨着股價下跌了5.9%,私人公司遭受了最大的損失。

Let's take a closer look to see what the different types of shareholders can tell us about Huadong Medicine.

讓我們更仔細地觀察一下不同類型的股東對華東醫藥的影響。

ownership-breakdown
SZSE:000963 Ownership Breakdown May 27th 2024
SZSE:000963所有權結構於2024年5月27日

What Does The Institutional Ownership Tell Us About Huadong Medicine?

機構投資者持有華東醫藥相當數量的股份。這意味着爲這些機構工作的分析師們已經觀察了股票,並且他們喜歡這隻股票。但是和其他人一樣,他們可能是錯誤的。當多個機構持有一隻股票時,總會存在它們在某個 '擁擠的交易' 中的風險。如果這種交易出現問題,則可能會有多個方面競相快速出售股票。在一個沒有增長曆史的公司中,這種風險更高。您可以看到華東醫藥的歷史收益和營業收入情況,請記住這只是故事的一部分。

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

As you can see, institutional investors have a fair amount of stake in Huadong Medicine. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Huadong Medicine's historic earnings and revenue below, but keep in mind there's always more to the story.

截止2024年5月27日,華東醫藥的歷史收益和營業收入增長情況。機構持股相當數量的股份向我們傳達了一個信息。本着 “優勢互補,均衡發展”的原則,我們將高品質資源極大程度地融入了我們的業務。

earnings-and-revenue-growth
SZSE:000963 Earnings and Revenue Growth May 27th 2024
對於華東醫藥而言,對沖基金擁有的股份不多。最大的股東是中國華大企業集團有限公司,持有公司42%的股份。杭州華東醫藥集團有限公司是第二大股東,擁有16%的普通股,中歐基金管理有限公司持有公司股份的約1.8%。

Hedge funds don't have many shares in Huadong Medicine. China Grand Enterprises, Inc. is currently the company's largest shareholder with 42% of shares outstanding. Hangzhou Huadong Medicine Group Co., Ltd. is the second largest shareholder owning 16% of common stock, and Zhong Ou Fund Management Co., Ltd holds about 1.8% of the company stock.

我們最近的數據表明,內部人員擁有華東醫藥股份有限公司股份不到1%。但是,我們注意到,內部人員可能通過私人公司或其他公司結構間接擁有利益。是一個大公司,所以即使擁有少量比例的持股,也可以在董事會和股東之間創造共識。這種情況下,內部人員擁有價值3100萬元的股份。同樣重要的是考慮最近的買賣情況。您可以點擊這裏查看內幕交易情況。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前2名股東擁有該公司的大部分所有權,這意味着他們足夠強大,可以影響公司的決策。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

我們的數據表明,私人公司持有公司的4.0%的股份。單單從這個事實上很難得出任何結論,因此它值得研究誰擁有這些私人公司。有時內部人或其他相關方通過單獨的私營公司持有上市公司的股份。

Insider Ownership Of Huadong Medicine

擁有27%股權的散戶,主要由個人投資者組成,對華東醫藥有一定的影響力。這些持股雖然相當可觀,但如果決定與其他大股東不一致,可能無法改變公司政策。

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少包括董事會成員。管理層最終向董事會負責。然而,經理們成爲執行董事會成員並不罕見,尤其是如果他們是創始人或首席執行官。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our most recent data indicates that insiders own less than 1% of Huadong Medicine Co., Ltd. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥31m worth of shares. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

始終值得考慮不同的人群持有公司股份的情況。 但是,如果要更好地了解華東醫藥,我們需要考慮許多其他因素。例如,持續存在的投資風險。我們已經確定了華東醫藥的1個警告信號,並且了解它們應該成爲您投資過程的一部分。

General Public Ownership

一般大衆所有權

With a 27% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Huadong Medicine. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

私人公司對華東醫藥的重要控制意味着公衆有更多的權力來影響管理和治理相關決策。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 58%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們可以看到,私人公司持有該公司發行的股份中的58%。單憑這一事實很難得出任何結論,因此值得研究誰擁有這些私人公司的所有權。有時,內部人員或其他相關方通過單獨的私人公司持有公共公司的股份。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Huadong Medicine better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Huadong Medicine , and understanding them should be part of your investment process.

始終值得考慮不同的人群持有公司股份的情況。 但是,如果要更好地了解華東醫藥,我們需要考慮許多其他因素。例如,持續存在的投資風險。我們已經確定了華東醫藥的1個警告信號,並且了解它們應該成爲您投資過程的一部分。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果您希望了解分析師在未來增長方面的預測,請務必不要錯過這份免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論